Abnormal Uterine Bleeding — Acute Hemodynamic Management

Key Points

• Exclude pregnancy-related bleeding before labeling the episode nonpregnant AUB.
• Hemodynamic status and bleeding rate matter more than the initial hemoglobin alone.
• Medical therapy is first line for most stable patients without a contraindication.
• Combined hormonal therapy, high-dose progestin, and tranexamic acid are major acute options.
• Use progestin-based therapy when estrogen is contraindicated.
• Consider an inherited bleeding disorder in adolescents or patients with a lifelong bleeding history.
• Uncontrolled hemorrhage requires early gynecology involvement and may need tamponade, embolization, hysteroscopy, curettage, or surgery.
• Treat iron deficiency and investigate the underlying PALM-COEIN cause after stabilization.

Algorithm

1. Assess hemodynamics, quantify ongoing bleeding, obtain IV access, and resuscitate as needed.
2. Obtain pregnancy testing immediately in reproductive-age patients.
3. Check CBC and type and screen; add coagulation and other testing based on history.
4. If unstable or bleeding is uncontrolled, involve gynecology early and prepare procedural hemorrhage control.
5. If stable, select combined hormonal therapy, high-dose progestin, or tranexamic acid according to contraindications and cause.
6. Use ultrasound and pelvic examination to identify structural or cervical pathology.
7. Escalate to tamponade, hysteroscopy, embolization, or surgery if medical therapy fails.
8. Arrange iron replacement and follow-up for definitive diagnosis and recurrence prevention.

Clinical Synopsis & Reasoning

Acute abnormal uterine bleeding is uterine bleeding of sufficient quantity to require immediate intervention. The first diagnostic branch is pregnancy status because ectopic pregnancy, miscarriage, retained products, placental disease, and postpartum hemorrhage require different pathways. In a reproductive-age patient, obtain a pregnancy test early unless pregnancy is impossible.

Assess hemodynamic severity before attempting to classify the cause. Tachycardia, orthostatic symptoms, syncope, pallor, delayed capillary refill, hypotension, and ongoing large-volume bleeding suggest clinically significant blood loss. Hemoglobin can initially underestimate acute hemorrhage, so resuscitation should not wait for a low laboratory value. Establish IV access, type and screen or crossmatch when bleeding is substantial, and activate transfusion support when shock or ongoing hemorrhage warrants it.

Once stabilized, organize the differential with the PALM-COEIN framework: polyp, adenomyosis, leiomyoma, malignancy or hyperplasia; coagulopathy, ovulatory dysfunction, endometrial causes, iatrogenic causes, and not otherwise classified. In adolescents or patients with lifelong heavy menses, easy bruising, postpartum bleeding, or procedural bleeding, consider an inherited bleeding disorder such as von Willebrand disease. Medication review should include anticoagulants, hormonal contraception, tamoxifen, and drugs that affect ovulation.

Pelvic examination assesses bleeding source, cervical lesions, trauma, retained foreign body, and uterine or adnexal findings. Transvaginal ultrasound is useful for structural pathology once the patient is stable. Endometrial sampling is indicated based on age and risk factors for hyperplasia or malignancy rather than simply because the bleeding is heavy.

Treatment Strategy & Disposition

Resuscitate first. Use isotonic fluid judiciously while arranging blood products for significant hemorrhage. In a hemodynamically unstable patient with ongoing uterine bleeding, involve gynecology early because medical therapy alone may be too slow.

For stable patients without contraindications, medical therapy is usually first line. High-dose combined estrogen-progestin oral contraceptives can rapidly stabilize the endometrium and reduce bleeding. High-dose oral progestin is effective and is preferred when estrogen is contraindicated, such as in many patients with significant thromboembolic risk. IV conjugated estrogen can control severe acute bleeding quickly in selected patients but should be used carefully because of thrombosis risk and generally with gynecologic guidance. Tranexamic acid reduces fibrinolysis and can be given orally or IV depending on severity and local protocol; avoid or individualize use in patients with active thromboembolic disease.

If medical therapy fails or bleeding is immediately life-threatening, procedural options include intrauterine balloon tamponade, dilation and curettage or hysteroscopy for selected structural causes, uterine artery embolization, and surgery. The correct procedure depends on fertility goals, suspected etiology, hemodynamics, and available expertise. A blind curettage should not be reflexively used for all AUB because it may not treat a structural lesion and can miss focal pathology.

Correct iron deficiency and arrange longitudinal evaluation after the acute episode. Patients with ongoing hemodynamic instability, transfusion requirement, severe symptomatic anemia, suspected malignancy, uncontrolled bleeding, or inability to maintain follow-up generally require admission. Stable patients whose bleeding is controlled can be discharged with a defined hormonal or antifibrinolytic regimen and gynecology follow-up.

Epidemiology / Risk Factors

• Abnormal uterine bleeding is a common cause of emergency and outpatient gynecologic care.
• Anovulatory bleeding is common at the extremes of reproductive age and with polycystic ovary syndrome.
• Leiomyomas and adenomyosis are frequent structural contributors.
• Inherited bleeding disorders are disproportionately common among adolescents with severe heavy menstrual bleeding.
• Chronic heavy bleeding frequently causes iron deficiency even before severe anemia is recognized.

Investigations

Therapeutic Options

Pharmacology

Prognosis / Complications

• Most acute episodes can be controlled with medical therapy when the patient is stable.
• Recurrence is common until the underlying ovulatory, structural, or coagulation disorder is treated.
• Iron deficiency can persist after bleeding stops and requires replacement.
• Persistent or recurrent AUB can reveal endometrial hyperplasia or malignancy, particularly in higher-risk patients.
• Fertility-preserving treatment is possible for many causes when acute hemorrhage is controlled promptly.

Patient Education / Counseling

• Explain the exact medication schedule because acute hormonal regimens often use higher initial doses and taper.
• Review estrogen and tranexamic-acid contraindications and thrombotic warning symptoms.
• Return immediately for syncope, chest pain, shortness of breath, soaking pads repeatedly despite treatment, or worsening weakness.
• Track bleeding frequency and pad or tampon use to help quantify recurrence.
• Take iron as prescribed and expect that rebuilding iron stores takes longer than stopping the bleeding.
• Keep gynecology follow-up even if the acute bleeding resolves because the cause still needs evaluation.

Notes

The acute and chronic AUB evaluations should not be confused. In the ED, the first job is to decide whether the patient is pregnant and whether the bleeding is hemodynamically dangerous. PALM-COEIN becomes most useful after those immediate questions are addressed.

Many patients leave the ED with bleeding improved but iron stores profoundly depleted. A normalizing hemoglobin does not guarantee restored iron. Ferritin assessment and iron replacement are important parts of definitive care, especially after prolonged heavy menses.

References

1. ACOG Committee Opinion: Management of Acute Abnormal Uterine Bleeding in Nonpregnant Reproductive-Aged Women — Link
2. ACOG Clinical Guidance — Link